Goldman Sachs
EVFM

Goldman Sachs’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

Goldman Sachs’s Portfolio EVFM Stock Details EVFM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,643
Closed -$8K – 6937
2022
Q1 		$8K Sell
1,643
-2,070
-56% -$13K ﹤0.01% 6499
2021
Q4 		$21K Sell
3,713
-2,287
-38% -$19.4K ﹤0.01% 6366
2021
Q3 		$67K Buy
6,000
+3,581
+148% +$45K ﹤0.01% 5991
2021
Q2 		$41K Sell
2,419
-14,378
-86% -$273K ﹤0.01% 6092
2021
Q1 		$441K Buy
16,797
+4,796
+40% +$218K ﹤0.01% 5212
2020
Q4 		$434K Buy
12,001
+10,365
+634% +$375K ﹤0.01% 4689
2020
Q3 		$58K Buy
1,636
+519
+46% +$22.6K ﹤0.01% 5170
2020
Q2 		$47K Buy
+1,117
New +$75.3K ﹤0.01% 5069
2017
Q3 		– Sell
-146
Closed -$7K – 6954
2017
Q2 		$7K Sell
146
-102
-41% -$17.9K ﹤0.01% 6680
2017
Q1 		$36K Buy
248
+67
+37% +$8.69K ﹤0.01% 6375
2016
Q4 		$18K Sell
181
-13
-7% -$1.35K ﹤0.01% 6674
2016
Q3 		$20K Sell
194
-20
-9% -$1.83K ﹤0.01% 6763
2016
Q2 		$19K Sell
214
-67
-24% -$6K ﹤0.01% 6737
2016
Q1 		$15K Buy
+281
New +$21.7K ﹤0.01% 6813
2015
Q4 		– Sell
-218
Closed -$159K – 7436
2015
Q3 		$159K Sell
218
-280
-56% -$301K ﹤0.01% 6162
2015
Q2 		$403K Sell
498
-133
-21% -$85.3K ﹤0.01% 5426
2015
Q1 		$466K Buy
631
+441
+232% +$282K ﹤0.01% 5206
2014
Q4 		$128K Buy
+190
New +$144K ﹤0.01% 6459

Other funds holding EVFM

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FWSM
First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Goldman Sachs's EVFM Position: Q2 2022 in Review

Goldman Sachs sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q2 2022, closing a stake of 1,643 shares — an estimated $8K sold.

Goldman Sachs first reported a position in EVFM in Q4 2014 and held it in 18 quarters. The position peaked at $466K in Q1 2015. 44 funds tracked by Wall St. Rank hold EVFM as of Q2 2022.

  • Goldman Sachs reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Goldman Sachs sold 1,643 Evofem Biosciences, Inc. Common Stock shares in Q2 2022, an estimated $8K.
  • Goldman Sachs first reported a position in Evofem Biosciences, Inc. Common Stock in Q4 2014 and held it in 18 quarters.
  • Goldman Sachs's Evofem Biosciences, Inc. Common Stock position peaked at $466K in Q1 2015.
  • 44 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q2 2022.

Based on Goldman Sachs's 13F filing for Q2 2022, filed 15 Aug 2022.